Tyrosine kinase inhibitors, which have changed the management of chronic myeloid leukemia (CML) patients during the last 10 years [151], control cell cycle and apoptosis through several mechanisms, including the regulation of CDH1 levels [122]. This evidence concerns the gene CDH1 and chronic myelogenous leukemia, BCR-ABL1 positive.